Sabrina Schweintzger1,2, Martin Koestenberger1,2, Axel Schlagenhauf3, Gernot Grangl1, Ante Burmas1, Stefan Kurath-Koller1, Mirjam Pocivalnik4, Hannes Sallmon2,5, Daniela Baumgartner1, Georg Hansmann2,6, Andreas Gamillscheg1. 1. Division of Pediatric Cardiology, Department of Pediatrics, Medical University of Graz, Austria. 2. European Pediatric Pulmonary Vascular Disease Network, Berlin, Germany. 3. Division of General Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria. 4. Pediatric Intensive Care Unit, Department of Pediatrics, Medical University of Graz, Graz, Austria. 5. Department of Pediatric Cardiology, Charité University Medical Center, Berlin, Germany. 6. Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany.
Abstract
BACKGROUND: Macitentan, a dual endothelin receptor antagonist (ERA), was approved in 2014 for the treatment of adults with idiopathic pulmonary arterial hypertension (PAH). Once-per-day dosing and low potential hepatic toxicity make macitentan an appealing therapeutic option for children with PAH, but reports on its use in pediatric patients are still lacking. METHODS: Prospective observational study of 18 children [10 male; median age: 8.5, minimum (min.): 0.6, maximum (max.): 16.8 years] with pulmonary hypertension (PH). Four of these 18 patients were treatment-naïve and started on a de novo macitentan therapy. The remaining 14/18 children were already on a PH-targeted pharmacotherapy (sildenafil or bosentan as monotherapy or in combination). Nine children who were on bosentan were switched to macitentan. We analyzed the 6-minute walking distance (6MWD), NYHA functional class (FC)/modified ROSS score, invasive hemodynamics, echocardiographic variables and the biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: The median follow up was 6 months (min.: 0.5, max.: 30). Macitentan treatment was associated with improvement of invasive hemodynamics, e.g., the ratio of mean pulmonary arterial pressure/mean systemic arterial pressure decreased from a median of 62% (min.: 30%, max.: 87%) to 49% (min.: 30%, max.: 69%), P<0.05; pulmonary vascular resistance index (PVRi) decreased from a median of 7.6 (min.: 3.3, max.: 11.5) to 4.8 Wood units × m2 body surface area (min.: 2.5, max.: 10), P<0.05. The tricuspid annular plane systolic excursion (TAPSE) increased from a median of 1.4 (min.: 0.8, max.: 2.8) to 1.9 (min.: 0.8, max.: 2.7) cm, (P<0.05). NT-proBNP values decreased from a median of 272 (min.: 27, max.: 2,010) to 229 (min.: 23, max.: 814) pg/mL under macitentan therapy (P<0.05). The 6MWD and NYHA FC/modified ROSS score did not change significantly. CONCLUSIONS: This is the first prospective study of macitentan pharmacotherapy in infants and children with PH <12 years of age. Except in one patient, macitentan treatment was well tolerated and was associated with improvements in invasive hemodynamics, longitudinal systolic RV function (TAPSE) and serum NT-proBNP values. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
BACKGROUND: Macitentan, a dual endothelin receptor antagonist (ERA), was approved in 2014 for the treatment of adults with idiopathic pulmonary arterial hypertension (PAH). Once-per-day dosing and low potential hepatic toxicity make macitentan an appealing therapeutic option for children with PAH, but reports on its use in pediatric patients are still lacking. METHODS: Prospective observational study of 18 children [10 male; median age: 8.5, minimum (min.): 0.6, maximum (max.): 16.8 years] with pulmonary hypertension (PH). Four of these 18 patients were treatment-naïve and started on a de novo macitentan therapy. The remaining 14/18 children were already on a PH-targeted pharmacotherapy (sildenafil or bosentan as monotherapy or in combination). Nine children who were on bosentan were switched to macitentan. We analyzed the 6-minute walking distance (6MWD), NYHA functional class (FC)/modified ROSS score, invasive hemodynamics, echocardiographic variables and the biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: The median follow up was 6 months (min.: 0.5, max.: 30). Macitentan treatment was associated with improvement of invasive hemodynamics, e.g., the ratio of mean pulmonary arterial pressure/mean systemic arterial pressure decreased from a median of 62% (min.: 30%, max.: 87%) to 49% (min.: 30%, max.: 69%), P<0.05; pulmonary vascular resistance index (PVRi) decreased from a median of 7.6 (min.: 3.3, max.: 11.5) to 4.8 Wood units × m2 body surface area (min.: 2.5, max.: 10), P<0.05. The tricuspid annular plane systolic excursion (TAPSE) increased from a median of 1.4 (min.: 0.8, max.: 2.8) to 1.9 (min.: 0.8, max.: 2.7) cm, (P<0.05). NT-proBNP values decreased from a median of 272 (min.: 27, max.: 2,010) to 229 (min.: 23, max.: 814) pg/mL under macitentan therapy (P<0.05). The 6MWD and NYHA FC/modified ROSS score did not change significantly. CONCLUSIONS: This is the first prospective study of macitentan pharmacotherapy in infants and children with PH <12 years of age. Except in one patient, macitentan treatment was well tolerated and was associated with improvements in invasive hemodynamics, longitudinal systolic RV function (TAPSE) and serum NT-proBNP values. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: R Channick; D B. Badesch; V F. Tapson; G Simonneau; I Robbins; A Frost; S Roux; M Rainisio; F Bodin; L J. Rubin Journal: J Heart Lung Transplant Date: 2001-02 Impact factor: 10.247
Authors: Ilja M Blok; Annelieke C M J van Riel; Arie P J van Dijk; Barbara J M Mulder; Berto J Bouma Journal: Int J Cardiol Date: 2016-11-09 Impact factor: 4.164
Authors: Rosa Laura E van Loon; Marcus T R Roofthooft; Hans L Hillege; Arend D J ten Harkel; Magdalena van Osch-Gevers; Tammo Delhaas; Livia Kapusta; Jan L M Strengers; Lukas Rammeloo; Sally-Ann B Clur; Barbara J M Mulder; Rolf M F Berger Journal: Circulation Date: 2011-09-26 Impact factor: 29.690
Authors: Martin Koestenberger; Gernot Grangl; Alexander Avian; Andreas Gamillscheg; Marlene Grillitsch; Gerhard Cvirn; Ante Burmas; Georg Hansmann Journal: Circ Cardiovasc Imaging Date: 2017-01 Impact factor: 7.792
Authors: Martin Koestenberger; William Ravekes; Allen D Everett; Hans Peter Stueger; Bernd Heinzl; Andreas Gamillscheg; Gerhard Cvirn; Arnulf Boysen; Andrea Fandl; Bert Nagel Journal: J Am Soc Echocardiogr Date: 2009-05-07 Impact factor: 5.251
Authors: Jasper Dingemanse; Patricia N Sidharta; Willis C Maddrey; Lewis J Rubin; Hani Mickail Journal: Expert Opin Drug Saf Date: 2013-11-22 Impact factor: 4.250
Authors: Georg Hansmann; Hannes Sallmon; Charles C Roehr; Stella Kourembanas; Eric D Austin; Martin Koestenberger Journal: Pediatr Res Date: 2020-06-10 Impact factor: 3.756